Heart failure & cardiomyopathiesCohort study

Sodium Glucose Co-Transporter 2 Inhibitors in Patients With Heart Failure and Transcatheter Aortic Valve Replacement

JACC AdvPublished

  • retrospective cohort analysis
  • propensity score matching
  • deidentified, aggregate patient data from the TriNETX research network

Authors' conclusion

Among CHF patients undergoing TAVR, SGLT2i use was not associated with a reduced risk of the primary composite outcome at 6-months and 1-year intervals.

Study context

Population
Patients ≥18 years old with congestive heart failure (CHF) who underwent a transcatheter aortic valve replacement (TAVR) procedureCHF patients undergoing TAVR identified, of whom 2,464 were on SGLT2 inhibitors therapy, 2,039 patients in each group after propensity score matching
Participants
21,828 patients
Exposure
SGLT2 inhibitors vs standard care in CHF patients undergoing TAVR
  • SGLT2 inhibitorsn = 2,039
  • standard caren = 2,039reference
Outcome
Composite of:
  • Acute myocardial infarction
  • Stroke
  • All-cause mortality
  • Acute CHF
Follow-up
6 months

Main finding

As reported in the abstract

Hazard ratio

0.79

P = 0.067

Observational data: associations, not effects.

Further findings

OutcomeHRP value
Acute myocardial infarction · 6 months · significantly lower risk with SGLT2 inhibitors0.69P = 0.043
All-cause hospitalization/emergency room visits · 6 months · significantly lower risk with SGLT2 inhibitors0.69P < 0.001
All-cause hospitalizations · 1 year0.73P < 0.001

Primary and individual endpoints · 1 year

No significant differences except for all-cause hospitalizations and urinary tract infections

Safety

OutcomeHRP value
Urinary tract infections · 1 year0.77P = 0.009

Original publication

Sodium Glucose Co-Transporter 2 Inhibitors in Patients With Heart Failure and Transcatheter Aortic Valve Replacement. JACC Adv. Published 17 January 2026. doi:10.1016/j.jacadv.2025.102462

Summarised from the published abstract; every number is checked against it